Renoprotective Benefit of Tolvaptan in Acute Decompensated Heart Failure Patients With Loop Diuretic-Resistant Status

BACKGROUND: While reduction of accumulated body fluid using loop diuretics is a commonly used therapeutic option for acute heart failure (AHF), some patients, especially those with chronic kidney disease (CKD), show significantly poor treatment response to loop diuretics. Tolvaptan (TLV) has shown e...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Tomohiko, Miura, Shin-ichiro, Shirai, Kazuyuki, Urata, Hidenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306139/
https://www.ncbi.nlm.nih.gov/pubmed/30627278
http://dx.doi.org/10.14740/jocmr3671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306139/
https://www.ncbi.nlm.nih.gov/pubmed/30627278
http://dx.doi.org/10.14740/jocmr3671

Ejemplares similares